Paller AS, Seyger MMB, Magariños GA, et al. - In this randomized, double‐blind, placebo‐controlled, phase III study (IXORA ‐PEDS), researchers tested the safety and effectiveness of ixekizumab (IXE), a high‐affinity monoclonal antibody that selectively targets interleukin‐17A, for moderate‐to‐severe paediatric psoriasis. Individuals aged 6 to < 18 years with moderate‐to‐severe plaque psoriasis have been randomized 2 : 1 to weight‐based dosing of IXE every 4 weeks (IXE Q4W, n = 115) or placebo (n = 56) through week 12, followed by open‐label IXE Q4W. According to findings, IXE offered rapid, statistically significant and clinically meaningful improvements to placebo in the skin, itch and health‐related quality of life that persisted in paediatric patients with moderate‐to‐severe plaque psoriasis for up to 48 weeks. IXE's safety profile was generally consistent with that of moderate-to-severe plaque psoriasis in adults. Thus, IXE may be an alternative therapeutic choice for moderate‐to‐severe paediatric psoriasis. No deaths have been reported in this analysis.